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                                               1.INTRODUCTION 
Glycogen synthase kinase 3 beta (GSK-3ȕ) a serine threonine kinase has multiple 
functions, including regulating cellular development ( Luo et al., 2014:fan  et al.,2014) and 
tissue protection. GSK-3ȕ is constitutively active in cells and its inactivation could be 
induced by phosphorylation at Ser-9 Growing evidence implicated that GSK-3ȕ is involved 
in brain tissue protection against ischemic injury or brain trauma. A selective GSK-3ȕ 
inhibitor could cause the phosphorylation at Ser-9 and inactivate GSK-3ȕ, thus provided a 
protective effect against transient cerebral ischemic injury. The inhibition of GSK-3ȕ was 
effective for regulating metabolic  disorders. Moreover, acute GSK-3ȕ inhibition was proved 
to be a novel therapeutic strategy for acute myocardial infarction in a diabetic model. Thus, 
GSK-3ȕ signaling pathway might be involved in cerebral ischemic injury. Glycogen synthase 
kinase 3 (GSK-3ȕ) dysregulation plays an important role in the pathogenesis of numerous 
disorders, affecting the central nervous system (CNS) encompassing both neuro inflammation 
(Golpich et al.,2015) and neurodegenerative diseases. Several lines of evidence have 
illustrated a key role of the GSK-3 and its cellular and molecular signaling cascades in the 
control of neuroinflammation.  GSK-3ȕ, one of the GSK-3 isomers, plays a major role in 
neuronal apoptosis and its inhibition decreases expression of alpha-Synuclei which make this 
kinase an attractive therapeutic target for neurodegenerative disorders. 
 Glycogen synthase kinase-3 (GSK-3), which is constitutively active and ubiquitously 
expressed in body tissues specially a (Darshit  et al.,2017) brain neuron and glia.GSK-3ȕ is 
expressed in most tissues. Expression of GSK-3ȕ is abundant in major adult brain parts like 
cerebral cortex, striatum, hippocampus and cerebellum. GSK-3ß is found in all brain region 
with varying mRNA levels. GSK-3ȕ is recognized as a crucial player in many cellular 
functions and its activity is tightly controlled by complex mechanisms that are dependent 
upon specific signalling pathways. Furthermore, GSK-3 gene dysfunction has been linked to 
a number of pathologies, including Alzheimer’s disease (AD). In particular, the involvement 
of GSK-3ȕ  in several key pathophysiological pathways leading to AD and 
neurodegenerative diseases has placed this enzyme in a central position in the context of 
these disorders. GSK-3 appears to be a cellular nexus that integrates several signalling 
systems, including several second messengers and a wide selection of cellular stimulants. 
 GSK-3 acts as a regulator of apoptosis and inflammation, known contributors to stroke-
induced cell death (Venna et al.,2015)  Loss of GSK-3 ȕ, not GSK-3alpha, suppressed 
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spontaneous neuronal death in extended culture models.  GSK-3ȕ inhibition reduces infarct 
size in adult stroke models and further interacted with pro-apoptotic transcription factors, 
such as p53, which upregulates  cytochrome C release and Caspase-3 activity providing more 
evidence of GSK-3ȕ's pro-apoptotic role following brain injury. Nonselective GSK-3 ȕ 
inhibition with lithium is neuroprotective and GSK-3 ȕ inhibitors are currently being tested in 
clinical trials for treatment of cognitive deficits and dementia. GSK-3beta is known to 
interact with the mitogen-activated protein kinase family (MAPKs) and promotes signalling 
after stress. Transforming growth factor-b-activated kinase-1 (TAK1) is a member of the 
MAPK family that is also known as mitogen-activated protein kinase kinase kinase-7. TAK1 
is activated by TGF-b, tumour necrosis factor-alpha and other cytokines including 
interleukin-1 (IL-1). TAK is also as upstream kinase of 5′ adenosine monophosphate-
activated protein kinase (AMPK), a key energy sensing kinase involved in stroke.  
  GSK-3 ȕ  dysregulation contributes to the pathogenesis of many disorders, such as several 
cancers and diabetes, (Avrahami  et al.,2013; Licht-Murava  et al.,2013) as well as 
neuroinflammatory and neurodegenerative diseases. Numerous studies have now implicated 
GSK-3 in control of various neuronal functions and have demonstrated that aberrant 
regulation of GSK-3 is involved in the etiology of neurodegenerative diseases, such as 
Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Alzheimer's 
disease (AD), as well as in brain aging. . Abnormal regulation of GSK-3 activity is reported 
in patients with AD, ALS, major depression, schizophrenia and bipolar disorder. 
Recent studies have suggested involvement of GSK-3ȕ in cerebral ischemia. (Darshit  et 
al.,2017) and demontsrated activation of GSK-3ȕ (Tyr216 phosphorylation) was found 
directly correlated to cerebral ischemia. The report has shown GSK-3ß inhibition was 
beneficial in cerebral ischemic condition. GSK-3ȕ  inhibition has also shown  neuroprotective 
effect by reducing infract size, Bax, caspase-3 and -9 activities both in in vitro and in vivo 
models of cerebral ischemia, suggesting a role of GSK-3ȕ involved in the mitochondrial 
pathway in pathology. Research revealed the role of GSK-3ȕ inhibition by NP00111, AR-A 
014418, and lithium in hippocampal neuroprotection through ERK and PPAR-Ȗ receptor 
signalling pathway in oxygen-glucose deprivation. This observation highlighted the link 
between GSK-3ȕ, ERK, and PPAR- Ȗ in cerebral ischemia. A study relating multiple 
pathways like calcium signalling (S100B - S100 calcium binding protein B) kinase pathway 
(MAPK/JNK-1, -2/p38), inflammatory pathway (NF-κȕ, TNF-α, COX-2, iNOS and ICAM- 
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1), and typical mitochondrial apoptosis pathway (SOD, cytochrome c caspase-9 and Bcl-2) 
were shown to have direct relation with GSK-3ȕ in cerebral ischemia. Inhibition of GSK-3ȕ  
showed neuroprotection through down-regulation of these multiple pathways. 
             The objective of the present study is to evaluate the neuroprotective effect of 
GSK- 3ȕ competitive and non competitive inhibitors in cerebral ischemic condition. 
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STROKE 
Stroke is a leading cause of death and disability, affecting 15 million people 
worldwide each year ( Zhang1 et al., 2015). Over 80% of stroke is caused by the 
obstruction of a cerebral artery by an endovascular embolus or thrombus formation. There are 
a number of underlying causes of stroke, including thrombosis, embolism,(Tang et al.,2014: 
Vital et al.,2015) stenosis and intracerebral hemorrhage. Embolic strokes are usually of 
extracranial origin and commonly result from clots formed in the heart due to atrial 
fibrillation. Thrombotic strokes are typically of intracranial origin and result from the rupture 
of an atheroma and subsequent injury of a downstream vessel, with the ensuing development 
of a thrombus in either a middle cerebral artery or a lacunar artery in the brain. Stroke 
recurrence occurs at a rate ranging between 4 and 14% and patients with risk factors, such as 
hypertension, are at higher risk of stroke recurrence. Up to 60–70% of recurrent strokes are of 
the same subtype as the initial stroke Ischemic stroke, due to interruption of the blood supply 
to the brain is one of the most important causes of morbidity and mortality worldwide. 
Currently, the control of systemic parameters, such as body temperature, blood pressure, and 
glycaemia, has considerably improved the outcome of stroke patients. In the absence of 
protective therapy, an early artery reperfusion, i.e. Mechanical or enzymatic thrombolysis, 
remains the primary goal of treatment for acute ischemic stroke. 
CEREBRAL ISCHEMIA 
Cerebral ischemia continues to be a major cause of death and the leading cause of long-term 
disability in humans. Acidotoxicity, ionic imbalance, and periinfarct depolarization also have 
a detrimental role in the initial phase of cerebral ischemia. Acidosis have long been 
recognized to aggravate brain injury associated with cerebral ischemia. A rapid drop of the 
pH to 6.5 or lower is frequently observed. The(Darshitet al.,2017)lack of oxygen supply 
promotes anaerobic glycolysis, which in turn leads to increased production of lactic acid. 
Accumulation of lactic acid, along with increased production of H+ from ATP hydrolysis, 
and release of H+ from presynaptic terminals, contribute to the acid build up in the brain and 
this leads to the activation of acid sensing ion channel (ASIC1a). Transport of sodium, 
calcium, and other ions is facilitated by pennexin 1 and 2 through P2X7 receptor, suggests 
that activation of both the receptors is found to be associated in cerebral ischemic stroke and 
aggravates acidosis and exitotoxicity. Both excitotoxicity and acidosis are linked to energy 
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crisis, oxidative stress, and apoptosis One of the crucial mediators of apoptosis involved in 
this cascade is GSK-3ß. Ischemia activated GSK-3ß by phosphorylation at Tyr216 up-
regulates apoptotic markers like p53, bad, Bax, and destroys ß-catenine thereby arresting 
neurogenic transcription factor activation. Linking all sequences and exploring the 
interrelationship of ASIC1a, P2X7 receptor, and GSK-3ß might have a beneficial effect 
indifferent phases of ischemic stroke. 
 
FIGURE.1. A schematic diagram of the major cell injury mechanisms involved in causing 
neuronal and glial cell death in cerebral ischemia.(Mattson et al.,2000). 
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TYPES OF CEREBRAL ISCHEMIA 
1) Global cerebral ischemia (Bacigaluppiet et al., 2010; Durukan&Tatlisuma et al., 2007). 
2) Focal cerebral ischemia 
Ischemic stroke (IS) is associated with a pronounced reduction in glucose and oxygen 
(O2) supply to cerebral tissue due to major arterial occlusion. Due to improper medical 
treatments, around millions of neuronal cells in the brain can die quickly as a consequence of 
excitotoxicity-mediated brain injury due to excessive glutamate release that excites neurons 
to death via induced overproduction of free radicals and massive inflammation generated 
from recruiting leukocytes and activated microglia cells. However, the acute inflammation 
and oxidative stress that accompanies the early stages of stroke can result in the activation of 
detrimental transcription factors (e.g., Nuclear factor kappa-B (NF-kB)) to disrupt the blood– 
brain barrier, a physical barrier within the brain providing the protection and regulation of 
homeostasis. It is well understood that brain glucose metabolism and (Narne et al., 2017) 
blood flow serves as bona fide indices of neuronal synaptic activity. Hence, a disruption in 
these activities explicitly correlates with an impaired synaptic transmission as observed in the 
hypoperfused(Hofmeijer et.al,,2012; vanPutten et al.,, 2012) and electrically silent ischemic 
penumbra. 
 Mitochondria constitute the hub of metabolic networks, owing to their central role in the 
generation of ATP and reducing power(NADH, FADH2), anaplerosis, Ca2+ homeostasis and 
free radical detoxification. In line with this, a series of metabolic disruptions occur during the   
CI/ R in the highly dynamic mitochondrial compartment of neurons following oxygen and 
glucose deprivation (OGD) and glutamate(Nicholls et al., 2009)induced excitotoxicity. It 
induce discernible changes in the levels endogenous metabolites and energy intermediates of 
core pathways of intermediary metabolism (Villa et al., 2013). Mitochondria are quantifiable 
sources of reactive oxygen species (ROS), alteration in metabolic fluxes aggravates existing 
oxidative and nitrosamine stress that befits bioenergetic failure, at the same time antioxidant 
defence goes awry due to an overwhelming production of ROS and reactive nitrogen species 
(RNS). These perturbations impinge on cellular transcriptome and elicit an adaptive cellular 
phenotype  CI/R Evidence indicates that inflammation(Martinez B et al.,2017) and immune 
response plays an important role in the outcome of ischemic stroke. Inflammation after stroke 
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involves leukocyte infiltration in brain parenchyma that contributes to cerebral damage. 
Peripherally derived mononuclear phagocytes, T lymphocytes, natural killer (NK) cells, and 
polymorph nuclear  leukocytes, which produce and secrete cytokines, can all contribute to 
central nervous system (CNS) inflammation and gliosis  Blood-derived leukocytes and 
resident microglia are the more activated inflammatory cells, accumulating in the brain tissue 
after cerebral ischemia, leading to inflammatory injury. Microglia, the major source of 
cytokines and other immune molecules of the CNS, are the first non-neuronal cells that 
respond to CNS injury, becoming phagocytic when fully activated by neuronal death. As 
cerebral inflammation is one of the earliest events in stroke, early intervention to modify the 
immune response may have a beneficial effect. 
ROLE OF GSK-3ß IN ISCHEMIC STROKE. 
Glycogen synthase kinase 3 beta (GSK-3β) has multiple functions, including regulating 
cellular development ( Guo et al.,2014; Jiang et al.,2014) and tissue protection. GSK-3β is 
constitutively active in cells and its inactivation could be triggered by phosphorylation at Ser-
9  Growing evidence implicated that GSK-3β is involved in brain tissue protection against 
ischemic injury or brain trauma. A selective GSK-3β inhibitor could cause the 
phosphorylation at Ser-9 and inactivate GSK-3β, thus provided a protective effect against 
transient cerebral ischemic injury. The inhibition of GSK-3β was effective for regulating 
metabolism disorders. Moreover, acute GSK-3β inhibition was proved to be a novel 
therapeutic strategy for acute myocardial infarction in a diabetic model. Thus, the GSK-3ß 
signalling pathway might be involved in cerebral ischemic injury in DM. 
Cerebral ischemic stroke arises due to the blockade of cerebral artery which involves in 
supplying blood to this brain region. Due to this(Darshit et al.,2017)blockade, massive 
reduction of cerebral blood flow leads to reduced oxygen and glucose delivery and hence 
leads to energy deprivation as well as accumulation of toxic metabolites. Nerve cells that do 
not store energy source, which is lacking in ischemia will lead to multiple initial 
consequences like metabolic stress, failure in energy production, and ionic transport 
dysfunction (both ATP dependent and independent). Vulnerability after ischemic insult 
depends on duration of insult, as the neurons die within a minute of severe exposure. 
Depending on duration of ischemic insult, focal or global as well as transient or permanent, 
several signalling pathways getting into act to alter the neuronal morphology. In the initial 
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phase of insult, defense mechanisms get activated and try to normalize the effect. During the 
subsequent phases, apoptosis signalling determines the cell fate.  
The time dependent change in gene expression (374 genes) of different pathways related to 
ischemia was assessed and shown to have a consistent change in Tumour necrotic factor 
receptor (TNFR) signalling pathway in all time intervals. Apart from TNFR signalling 
pathway genes, protein tyrosine kinase 2 (PyK2), protein kinase C (PKC), E2F transcription 
factor 1 (E2F1), vascular endothelial growth factor-A (VEGF-A), and many others were also 
changed at different time intervals. There were significant morphological alteration and 
infract volume found prominent at 12 and 24 HR, rather than at 3 hr. Several studies showed 
importance of reactive oxygen species (ROS) during initial phase in ischemia and its 
involvement in cellular signalling pathways. 
There is sufficient evidence suggesting involvement of GSK-3ß in cerebral ischemia. 
Research reveals that over activation of GSK-3 β (Tyr216 phosphorylation) was found 
directly correlated to cerebral ischemia. Further, lithium induced GSK-3ß inhibition showed 
protective mechanism in cerebral ischemia. This observation suggests that the reduction of 
GSK-3ß activity improves brain cell survival. Activity of lithium in cerebral ischemia 
suggests that the PI3K/AKT/GSK-3ß link correlates in cerebral ischemia. Other studies 
involves inhibition of GSK- 3ß inhibition by Chir025 showed neuroprotective effect by 
reducing infract size, Bax, caspase-3 and -9 activities both in in vitro and in vivo models of 
cerebral ischemia, suggesting role of GSK-3ßinvolved in the mitochondrial pathway in 
pathology. Research revealed the role of GSK-3ß  inhibition by NP00111, AR-A 014418, and 
lithium in hippocampal neuroprotection through ERK and PPAR receptor signalling pathway 
in oxygen-glucose deprivation. This observation highlighted the link between GSK-3ß, ERK, 
and PPAR in cerebral ischemia. A study relating multiple pathways like calcium signaling 
(S100B - S100 calcium binding protein B) kinase pathway (MAPK/JNK-1, -2/p38), 
inflammatory pathway (NF-(kappa) ß, TNF-alpha, COX-2, iNOS and ICAM-1), and typical 
mitochondrial apoptosis pathway (SOD, cytochrome c caspase-9 and Bcl-2) were shown to 
have direct relation with GSK-3ß in cerebral ischemia. Inhibition of GSK-3ß showed 
neuroprotection through down-regulation of these multiple pathways. 
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Activation of GSK-3ß can also induce apoptosis by caspase independent pathway involving 
p53 - a transcription factor which can regulate signalling dependent transcription Of genes. 
GSK-3ß forms a complex with nuclear p53 through binding to c-terminal region and 
phosphorylates Ser33, Ser315, and Ser376 residues. Upon interaction ofGSK-3ß with p53, 
short lived p53 will stabilize by variety of post translational modification such as 
phosphorylation, methylation, glycosylation, acetylation, sumoylation, and ubiquitination. 
GSK-3ß regulates p53 by phosphorylation of p53 specific E3 ubiquity ligase MDM2. In 
stroke, GSK-3ßhas been reported to be involved in neuronal cell death, whereas treatment 
with GSK-3ßinhibitors in the acute state reduces infarction volume and improves 
neurobehavioral function. In the chronic state,GSK-3ßinhibitors promote neurovascular 
remodelling after stroke and improve post ischemic stroke sequel. 
It have been reported that inhibition of glycogen synthase kinase-3 (GSK-3) activities is 
neuroprotective against ischemic stroke. The kinase activities of GSK-3 are negatively 
regulated by phosphorylation(Chern  et al.,2014; Wang et al.,2014) of GSK-3a at Ser21 
and/or GSK-3b at Ser9. GSK-3 can be inhibited through direct binding to the ATP dependent 
magnesium-sensitive catalytic site of the enzyme and/or indirectly through enhanced serine 
phosphorylation of GSK-3 iso forms by multiple mechanisms. Inhibition of GSK3 rescues 
not only neurogenesis, but also hippocampal depending learning. Conversely, increased 
GSK3 activity contributes to generate a neuroinflammatory environment and also impairs 
adult neurogenesis. These results support the idea that inhibition of GSK3 is a potential target 
for treating ischemic stroke. 
NEUROINFLAMMATORY PATHWAYS IN ISCHEMIC STROKE 
Inflammation plays an vital role in the pathogenesis of ischemic stroke and other forms of 
ischemic (Jin et al.,2013) brain injury. Cerebral ischemia triggers a series of 
proinflammatory molecular and cellular events, such as rapid activation of resident cells, 
infiltration of various types of inflammatory cells into the ischemic brain tissue, and 
production of proinflammatory mediators, including cytokines and chemokines. Chemokines 
are small, inducible, secreted, proinflammatory cytokines that act primarily as chemo 
attractant sand activators of granulocytes, macrophages, and other inflammatory cells. 
Chemokines constitute a large family of(Kim et al.,2014) structurally related cytokines. 
Chemokines belong to a rapidly expanding family of cytokines. Their primary function is to 
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control the positioning of cells in tissues and to recruit leukocytes to the site of inflammation. 
Some of the study reported that levels of a variety of chemokines such as monocyte 
chemoattractantprotein-1 (MCP-1) increased in animal models of ischemia and patients with 
stroke. 
LINK OF GSK-3ß AND INFLAMMATION IN STROKE 
GSK-3 acts as a regulator of apoptosis and inflammation, known contributors to stroke-
induced cell death (Venna et al,2015:Benashsklet al.,2015) Loss of GSK-3b, not GSK-3a, 
suppressed spontaneous neuronal death in extended culture models. Nonselective GSK-3b 
inhibition with lithium is neuroprotective and GSK-3b inhibitors are currently being tested in 
clinical trials for treatment of cognitive deficits and dementia. GSK-3beta is known to 
interact with the mitogen-activated protein kinase family (MAPKs) and promotes signalling 
after stress. Transforming growth factor-b-activated kinase-1 (TAK1) is a member of the 
MAPK family that is also known as mitogen-activated protein kinase kinase kinase-7. TAK1 
is activated by TGF-b, tumour necrosis factor-a (TNF-a), and other cytokines including 
interleukin-1 (IL-1). TAK is also an upstream kinase of 5′ adenosine monophosphate-
activated protein kinase (AMPK), a key energy sensing kinase involved in stroke. We found 
that inhibition of TAK1 is neuroprotective after focal ischemia (White et al. 2012). Our 
previous work demonstrated that neuroprotective effects of TAK1 inhibition are independent 
of its activation of AMPK. 
GSK-3ß IN RELATION WITH MICROGLIA ACTIVATION AND 
NEUROINFLAMMATION 
 Proinflammatory cytokines are major central functioning molecules responsible for 
neurodegenerative disorders including PD. Microglia are the one which recruits toxic 
cytokines and(Darshit et al.,2017) other pro inflammatory mediators in the brain during 
pathology and responsible for neuronal loss. Both animal models and human PD patients 
showed activated microglia in SN brain region. Activated microglia up-regulates number of 
pro inflammatory cytokines like IL-1ß, IL-2, IL-6, TNF-ð, as well as transcription factor NF-
κß which in turn up-regulates various other genes responsible for propagation of PD 
pathology. Suppression of inflammatory response. Through activated microglia showed 
beneficial effect against toxic challenge in PD pathology. Inflammatory response activated by 
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microglia is regulated by GSK-3ß.GSK-3ß acts as a centre bridge in a wide spectrum of 
signalling mechanism. Pro inflammatory cytokine production is enhanced from activated 
microglia by activation of GSK-3ß. Apart from cytokine production, GSK-3ß also promotes 
apoptosis through caspase dependent (caspase-3) and independent (p53) mechanisms, NF-κß 
mediated transcription, and several other signalling pathways discussed earlier to enhance 
progressive neuronal loss in PD. Inhibition of GSK-3ß can reverse neuroinflammation 
mediated through activated microglia. The anti inflammatory effect of GSK-3ß seems to be 
mediated through downregulation of a major pro inflammatory marker like TNF-ά. Other 
proposed mechanism of the neuroprotective effect of GSK-3ß is through NF-κß, 
PI3K/Akt/JNK signalling pathways. 
ROLE OF GSK-3ß AND APOPTOSIS IN ISCHEMIA 
GSK-3 acts as a regulator of apoptosis and inflammation, known contributors to stroke-
induced cell death. Glycogen synthase kinase 3β which is inhibited by activating Akt, hence 
making it a key target of thePI3K/Akt survival signalling pathway GSK-3β is involved in 
multiple cellular processes; GSK-3β inhibition reduces infarct size in adult stroke models and 
further interacted with pro-apoptotic transcription factors, such as p53, which upregulates 
cytochrome C release and Caspase-3 activity  providing more evidence of GSK-3β's pro-
apoptotic role following brain injury .Glycogen synthase kinase (GSK-3β), which participates 
in a myriad  of pathways throughout the central nervous system,(Li L et al.,2015; Doycheva 
et al.,2015) can be either neuroprotective or neurodegenerative depending on the site of 
phosphorylation; GSK-3β activity is increased by phosphorylation of tyrosine-216  and 
decreased by serine-9 phosphorylation While there is substantial evidence  that GSK-3β 
inhibition reduces neuronal apoptosis  experimental evidence of GSK-3β's effects6 on BBB 
stabilization and attenuation of inflammation are limited. 
Mitochondria serve as a mechanical tool for indication of ROS and subsequent signalling  
Cytochrome c, a mitochondrial protein and component of respiratory chain, is an intermediate 
in mitochondrial mediated cell death signaling. Cytochrome c gets released from 
mitochondria into the cytosol and activates caspase proteins for apoptosis of neurons, which 
are found in hippocampal CA1 region subjected to transient focal cerebral ischemia. Released 
cytochrome c forms apoptosome by interacting with apoptosis activating factor 1 (Apaf1), 
cell death protein-4 (CED-4), and dATP [107, 108]. This apoptosome activates caspase-9  
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which initiates caspase cascade by activating caspase-3, -2, -6, -8 and -10. Caspase activated 
DNAse (CAD), which is activated by caspase-3, then starts fragmenting \DNA. Apart from 
CAD, activation of caspase cascade leads cleavage of Poly (ADP ribose) polymerase(PARP), 
DNA fragmentation, and apoptosis. Function of PARP is dependent on NAD and can cause 
depletionin PARP overproduction, which in turn can deplete ATP stores and leads to energy 
failure. Apart from cytochrome-C, a second mitochondria-derived activator of caspase 
(Smac) also takes part in caspase cascade. Unlike cytochrome c and Smac, inhibitor of 
apoptosis protein (IAP). Suppresses apoptosis by preventing the cleavage of procaspase and 
inhibits caspase activity. Activity of IAP is inhibited by Smac which binds to IAP and 
promotes caspase-3 activity. 
There are other mediators that coincide in apoptosis like the Bcl-2 family proteins, which 
moderate apoptotic signalling by regulating mitochondrial membrane permeability. Studies 
also demonstrated that B cell lymphoma-2 (Bcl-2) family proteins regulate permeability 
transition pore (PTP) that is believed to release cytochrome c from mitochondria. Among 
Bcl-2 family proteins, Bcl-2 associated X protein (Bax), Bcl-XS, Bcl-2 homologues 
antagonist killer (Bak), BH3 interacting-domain death agonist (Bid), and Bcl-2 associated 
death promoter (Bad) are proapoptotic and facilitate cytochrome c release through PTP. 
Whereas, Bcl-2, and Bcl-XL have antiapoptotic activity, which blocks the release of 
cytochrome-c from mitochondria. Another neurotoxic material in cerebral ischemia is 
glutamate excitotoxicity. It is evident that elevated level of glutamate found in brain after 
cerebral ischemia leads to over stimulation of N-methyl D-aspartate receptor (NMDAR), 
which drives excitotoxic neuronal cell death. At the beginning phase of cerebral ischemia, the 
lack of oxygen and glucose leads to energy deprivation and subsequent failure of ATP 
dependent ion pumps. Following this alteration of electrolyte homeostasis, glutamate 
transport will be arrested. Hence accumulation of excess glutamate in extracellular 
compartment will over stimulate NMDAR and the further increase of calcium influx results 
in calcium mediated signalling by activating several intracellular enzymes and ultimate 
failure of mitochondria, generation of ROS, neuroinflammation, and apoptosis. Cerebral 
ischemia also activates other signalling pathways like p53, JNK \, c-jun, p38, CDK5, calpain, 
mTOR, hedgehog, notch, ERK-1, -2, PI3K/AKT/GSK-3, and many others. Upon activation 
of those pathways, downstream signalling will further propagate apoptosis 
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Hydrogen sulfide enhances N-methyl-D-aspartate receptor (NMDAR) -mediated responses, 
and facilitates the induction of the long-term potentiation of hippocampal neurons. However, 
cell culture( Dai1 et al.,2015; Xu1 et al.,2015) experiments have shown that high 
concentrations of hydrogen sulfide induce proapoptotic processes in hippocampal neurons by 
modulating the excitability of NMDARs. These findings of the effects of hydrogen sulfide on 
hippocampal neurons can be explained by the selective modulation of the NMDAR subunits, 
NR2A and NR2B. The activation of NR2A on synaptic neurons promotes the survival of 
hippocampal neurons via cAMP response element-binding protein (CREB) and 
phosphatidylinositol 3 -kinase (PI3K) -Akt signaling pathways, whereas the activation of 
NR2B on extrasynaptic neurons promotes neuronal apoptosis via the downregulation of 
CREB and the activation neuronal nitric oxide synthase (nNOS) - and JUN-mediated gene 
expression. The phosphorylation of the Akt serine-threonine kinase (also known as protein 
kinase B), a downstream target of PI3K, upregulates the phosphorylation of BAD, caspase-9, 
NF-κB, and Gsk-3β, which inhibits neuronal apoptosis. 
GSK-3ß IN RELATION TO MITOCHONDRIAL DYSFUNCTION 
Mitochondria are an important organelle for energy generation through ETC. Complex-I is 
involved in oxidative phosphorylation process and is the main site for the generation Of ROS 
through electron transfer to oxygen, generating O2-, and H2O2 during oxidative stress in PD. 
In one of the models of PD pathology, MPTP is metabolized by mono amino oxygenase B 
(MAOB) into a toxic substance named 1-methyl-4-phenylpyridinium (MPP+), which is then 
selectively taken up by the dopamine transporter.MPP+ accumulates in mitochondria and 
generates ROS by inhibiting complex-I and the destruction of dopaminergic neurons. GSK-
3ß is found more active in mitochondria than cytosol and initiates mitochondrial dysfunction. 
Functioning of GSK-3ß in mitochondria is not understood properly. However, research 
suggests that GSK-3ß controls ROS production through mitochondrial complex-I and 
regulates cell survival, and during pathology (MPTP and rotenone),are  increased GSK-3ß 
activity blocks the complex-I activity and subsequent ROS production in SN dopaminergic 
neurons. Inhibition of GSK-3ß activity in MPTP and rotenone model protects dopaminergic 
neurons through recovering mitochondrial functioning and subsequent suppression of ROS 
production 
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GSK  INVOLVED IN DIFFERENT DISEASE 
GSK-3ß dysregulation contributes to the pathogenesis of many disorders, such as several 
cancers, diabetes, (Avrahami  et al.,2013: Licht-Murava  et al.,2013) and neuroinflammatory, 
neurodegenerative diseases. Neuroinflammation defined as a highly regulated biological 
response to harmful stimuli such as infectious agents and tissue injury is characterized by 
increased glial activation, pro-inflammatory cytokine concentration, blood–brain-barrier 
permeability, and leukocyte invasion.  
Numerous studies have now implicated GSK-3 in control of various neuronal functions and 
have demonstrated that aberrant regulation of GSK-3 is involved in the etiology of 
neurodegenerative diseases, such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), 
multiple sclerosis, and Alzheimer's disease (AD), as well as in brain aging. Transgenic mice 
expressing elevated GSK-3 activity display memory deficits, reduced brain size and 
alterations in mood behaviour and social interactions. Abnormal regulation of GSK-3 activity 
is reported in patients with AD, ALS, major depression, schizophrenia and bipolar disorder. 
The mechanisms linking GSK-3 with pathogenesis likely involve regulation of targets that 
are directly or indirectly controlled by GSK-3. Thus, ‘normalization’ of GSK-3 activity 
emerges as a promising therapy for treatment of neurodegenerative and behaviour disorders. 
Inhibition of GSK-3 results in beneficial outcomes in multiple in vivo models. 
Neurotherapeutic effects of GSK-3 inhibition in  invivo animal models or patients. 
TABLE:1   
Neuro 
pathology 
Biological activity of 
GSK-3 inhibition Animal models 
Alzheimer's 
disease (AD) 
 Ameliorates Aβ 
pathology 
 Reduces tau 
phosphorylation 
 Improves learning 
and memory 
 Attenuates 
inflammation 
 Neuroprotective 
 FTDP-17 tau transgenic mice 
 APP/PS1 mice 
 hAPP mice 
 Rats injected with preformed β-amyloid 
 hTau (T44) mice 
 3xTg mice 
 GSK-3β mice 
 Postnatal rats 
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activity 
Amyotrophic 
lateral sclerosis 
(ALS) 
 Attenuates motor 
neuron death 
 Induces clearance of 
protein aggregates 
 Improves learning 
and memory 
 Human ALS patients 
 G93A-SOD1 mice 
Bipolar disorder 
(BD) and 
Depression 
 Anti-depressive 
activity 
 Neuroprotective  
activity 
 Reduces the 
prevalence of AD 
 Mood stabilizer 
(Lithium salts) 
 
 Human BD patients 
 “Clock mutant” mice- hyperactivity induced by 
amphetamine/chlorodiazepoxide/methamphetami
ne 
Cerebral 
ischemia (CI) 
 Attenuates neuronal 
death 
 Reduces infraction 
size 
 Reduces 
inflammation 
 Neuroprotective 
activity 
 Improves behavioral 
functions 
 Ischemic stroke rat 
 Rats subjected to permanent middle cerebral 
artery occlusion 
 Rats with hypoxia–ischemia brain injury 
Epilepsy 
 Reduces the 
development of 
hippocampal 
Sclerosis (lithium 
salts)  Rats injected with kainite 
Fragile X  Reduces audiogenic  Mice with mutated Fmr1 protein 
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syndrome (FXS) seizures frequency 
 Improves learning 
and memory 
 Improves behavioral 
functions 
 Neuroprotective 
activity 
 Drosophila with mutated FMR1 protein 
Huntington's 
disease (HD 
 Improves motor 
performance 
 Reduces 
polyglutamine 
toxicity 
 Neuroprotective 
activity 
 R6/2 mice (expressing mutated huntingtin) 
 Drosophila expressing mutated huntingtin 
Neuropathic pain 
 Anti hyperalgesic 
activity 
 Mice with partial ligation of the sciatic nerve 
(PSNL 
Parkinson's 
disease (PD) 
 Promotes dopamine 
neurons 
differentiation  Mice treated with neurotoxin MPTP 
Schizophrenia 
 Neuroprotective 
activity Mice treated with stereotoxic injection 
Spinal muscular 
atrophy (SMA) 
 Maintains motor 
neuronal survival  Fibroblasts derived from SMA patients 
Spinocerebellar 
Ataxia type 1 
(SCA1) 
 Improves motor 
coordination 
 Improves learning 
and memory  SCA1 (154Q/2Q) mice 
Traumatic brain 
injury (TBI) 
 Anti-depressive 
activity  Traumatic brain injury in mice 
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ARA014418: 
 
 
Figure.2.Chemical structure of ARA014418 (GSK-3β Inhibitor VIII CAS 487021-52-3) 
 
TDZD8: 
 
 
 
Figure.3.Chemical structure of TDZD8(GSK-3β Inhibitor I CAS 327036-89-5) 
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3. OBJECTIVES & PLAN OF STUDY 
 
The present study has been designed to address the following objectives  
1. To study the effect of AR-A014418 And TDZD-8, GSK-3β inhibitor on cerebral ischemic 
condition by behavioural assessment.  
2. To evaluate the neuroprotective activity mechanism of GSk3-β inhibitors in cerebral 
ischemia by exploring the anti-inflammatory pathways.  
             
            
            
   2hr         
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Western blot 
- gsk-3β , pgsk-3β ,  akt , 
pakt                                                             
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Phase-1 
Inducing ischemia by MCAo (middle cerebral artery occlusion) model and drug treatments 
(Güzel et al.,2014; Rölz et al.,2014) 
Phase-2 
Assesment of GSK-3 β inhibition effect through measuring a neurobehavioral studies 
using following parameter.  
2.1  Neurological deficit score ( Bederson et al., 1986) 
2.2   locomotor activity ( Borlongan et al.,1995; Cahill et al.,1995) 
2.3  Gripstength ( Gellman et al.,1989) 
2.4   Elevated Plus Maze ( Vécsei et al.,1990) 
Phase-3 
3.1 Evaluation of anti-inflammatory mechanism of GSK-3 β inhibition through 
measuring-IL-1β, TNF-α.through ELISA. 
3.2  Expression of protein measurement by  Western blot.   
GSK-3β , PGSK-3β ,  Akt , PAkt 
3.3 Apoptotic pathway measurement through analysing Caspase -3 activity assay. 
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4. MATERIALS & METHODS 
Materials: 
 
chemicals&tools used                                       Company name                          
ARA014418   (CAS 487021-52-3)     Santa Cruz 
TDZD 8 (CAS 327036-89-5)      Santa Cruz 
Crushing forceps       Finetools 
Bonney forceps       Finetools 
Adson tissue forceps       Finetools 
Adson teeth forceps       Finetools 
Horton adson forceps       Finetools 
Retractors        Finetools 
Scalpels        Finetools 
Microvessel clips       Finetools 
Scissors         Finetools 
Silicon         Anabond  
Caspase assay activity kit      Biovision inc 
elisa kit         R&d systems 
Temed         sigma-aldrich 
Acrylamide/bis solution      Bio-red 
Ammonium persulfate      sigma-aldrich  
Peroxide solution       thermo scintific  
Luminal enhancer solution      thermo scintific 
Glycine        sigma-aldrich 
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Methods:  
4.1. Animals  
Male Sprague-Dawley rats (290-340) used in the study were housed in individual 
polypropylene cages in a well ventilated room (air cycle: 15/hr) under an ambient 
temperature of 23±2ºC and 40-65% RH, with a 12:12 h light/dark artificial photo period. 
They were provided with food and purified water . All the animals were acclimatized atleast 
for 7days to the laboratory conditions prior to experimentation. Guidelines of “guide for the 
care and use of laboratory animals ” were strictly followed throughout the study. Institutional 
animal ethical committee (IAEC), PSG Institute of medical science and research, Coimbatore 
,approved the study.  
4.2. Surgical procedure 
Focal cerebral ischemia was induced by middle cerebral artery occlusion with minor 
modifications. Rats were anesthetized with ketamine (90mg/kg)  and xylazine (15mg/kg).The 
left common carotid artery was exposed at the level of external and internal carotid artery 
bifurcation. 4-0 nylon monofilament was used and its tip was made round headed by 
exposing it to flame. The Filament was coated with Anabond silicone gel and inserted into 
the external carotid artery and advanced to the internal carotid artery for a length of about 20–
21 mm until a slight resistance was felt. On achieving occlusion, the filament was held in 
place with ligature and the external incision was sutured temporarily. After 2 h of ischemia 
the rats were anesthetized, suture was opened, the filament was pulled out and reperfusion in 
internal carotid artery was ensured visually. Throughout the surgical procedure, body 
temperature was measured by inserting a thermometric probe into the rectum of rat and it was 
maintained at 37±0.5 °C using thermostatically controlled heating blanket. Animals were 
then kept in a cage with a heating lamp, which maintained the cage temperature between 
29±1 °C for another 1 h to counteract any possible hypothermic effect. In the sham-operated 
(SO) group, external carotid artery was surgically prepared for insertion of filament, but the 
filament was not inserted (Babu and Ramanathan, 2009). 
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Groups and treatments : 
Table.2 
Number  Group + Treatment  
1 MCAO + AR-A 014418  
30µm/kg   
2 MCAO + AR-A 014418  
 60µm/kg   
3 MCAO + TDZD dose 1500µm/kg 
4.3. Neurobehavioral paradigms 
4.3.1. Neurological deficit(Bederson et al., 1986) 
Neurological deficit were assessed by following score pattern after 24 hrs of ischemic 
reperfusion (IR) 
Neurological deficits (6-point scale) 
• 0 = No neurological deficit 
• 1 = Failure to extend left forepaw fully 
• 2 = Circling behaviour 
• 3 = Falling to the left 
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• 4 = No spontaneous walking with a depression 
• 5 = Death 
4.3.2. Loco motor activity 
After 168 hrs (7 days) of IR, the rats will be placed in the open field apparatus for recording 
the locomotion. The locomotor activity will be measured using an open field test. The 
behavioural parameters measured in open field test were Rearing ,Grooming, No.of 
ambulations, Time spent central compartment.( Borlongan et al.,1995; Cahill et al.,1995) 
4.3.3. Grip strength measurement 
After 168hrs(7 days) of IR the experimental animals , grip strength test by using bioseb grip 
strength meter was used to study of neuromuscular functions by determining maximal peak 
force developed by rodent were measured in units grams.( Gellman et al.,1989) 
4.3.4  Elevated plus maze 
Elevated plus maze test 
The elevated plus maze test (EPM) consisted of two open arms (35 × 5 cm) crossed with two 
closed arms (35 × 5 ×20 cm). The arms were connected together with a central square of 5 × 
5 cm. The apparatus was elevated to the height of 50 cm in a dimly illuminated room. 
Animals were placed individually at the end of either of the open arms facing away from the 
central platform. The time taken by each animal to move from open arm to either of the 
closed arms was recorded. This duration of time was called transfer latency (TL). If the 
animal did not enter into any of the enclosed arms within 120 s, it was gently pushed into any 
of the enclosed arms and TLwas considered as 120 s. Later the animal was allowed to explore 
the plus maze for 5 min and send back to its home cage. ( Vécsei et al.,1990) 
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4.4. Probable mechanism of neuroprotection 
4.4.1 Western blot 
Western Blot Analysis for Protein Detection Cells were lysed in RIPA buffer along with 
protease and phosphatise inhibitor cocktail. Samples were kept on ice for 15– 30 min 
followed by sonication and centrifugation at 12,000 rpm for 5 min. The supernatant solution 
was taken and assayed for total protein content by Bradford’s method. Equal protein 
concentration (20 μg) was used for SDS polyacrylamide gel electrophoresis. Proteins were 
transferred to a nitrocellulose membrane and blocked with 5 % bovine serum albumin 
prepared in TBST buffer for 3 h. The blocked membrane was incubated with primary 
antibody against Akt1 (1:750), S473p-Akt1 (1:1000), GSK-3β (1:500), S9 p-GSK-3β 
(1:1000), β-catenin (1:500), and reference protein β-actin (1:1000) for 2 h at room 
temperature. Following that, goat anti-rabbit IgG-HRPand goat anti-mouse IgG1-HRP 
secondary antibodies were added to the membrane in separate procedures according to the 
primary antibody used in the previous step and incubated for 1 h at room temperature. The 
membrane was developed and detected by Gel Dock system, G: Box (Syngene, 
Frederick,MD, USA). Row volume was considered for analysis. 
4.4.2GENERAL ELISA PROTOCOL 
Plate Preparation 
1. Dilute the Capture Antibody to the working concentration in PBS without carrier protein. 
Immediately coat a 96-well micro plate with 100 μL per well of the diluted Capture 
Antibody. Seal the plate and incubate overnight at room temperature. 
2. Aspirate each well and wash with Wash Buffer, repeating the process two times for a total 
of three washes. Wash by filling each well with Wash Buffer (400 μL) using a squirt bottle, 
manifold dispenser, or auto washer. Complete removal of liquid at each step is essential for 
good performance. After the last wash, remove any remaining Wash Buffer by aspirating or 
by inverting the plate and blotting it against clean paper towels. 
3. Block plates by adding 300 μL of reagent diluent to each well. Incubate at room 
temperature for a minimum of 1 hour. 
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4. Repeat the aspiration/wash as in step 2. The plates are now ready for sample addition. 
Assay Procedure 
1. Add 100 μL of sample or standards in reagent diluent, or an appropriate diluent, per well. 
Cover with an adhesive strip and incubate 2 hours at room temperature. 
2. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
3. Add 100 μL of the Detection Antibody, diluted in reagent diluent, to each well. Cover with 
a new adhesive strip and incubate 2 hours at room temperature. 
4. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
5. Add 100 μL of the working dilution of Streptavidin-HRP to each well. Cover the plate and 
incubate for 20 minutes at room temperature. Avoid placing the plate in direct light. 
6. Repeat the aspiration/wash as in step 2. 
7. Add 100 μL of Substrate Solution to each well. Incubate for 20 minutes at room 
temperature. Avoid placing the plate in direct light.  
8. Add 50 μL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing.  
9. Determine the optical density of each well immediately, using a microplate reader set to 
450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength 
correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 
nm. This subtraction will correct for optical imperfections in the plate. Readings made 
directly at 450 nm without correction may be higher and less accurate.  
4.4.3. Caspase activity assay 
Cells were harvested and lysed in 50 µl of lysis buffer by incubating on ice for 10 min. 
Centrifugation at 10,000×g for 2 min was done to remove cell debris. The supernatant extract 
was taken, and protein measurement was done by Bradford’s method. Total protein (100 µg) 
was used in 50 µl of cell lysis buffer. To this, 50 µl of 2× reaction buffer containing 10 
mMDTT and 5 µl of 4 mM of DEVD-pNA (caspase-3 substrate) was added and incubated at 
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37 °C for 90 min. Absorbance was measured at 405 nm by Multiskan™ GO multiplate 
reader(Thermo Scientific, Waltham, USA). The fold change in enzyme activity was measured 
5. Statistical Analysis 
The data are expressed on mean ±SD.The results will be analysed through one-way analysis 
of variance (ANOVA) followed by Tukey’s multiple comparison test to assess the statistical 
significance of the differences among the study groups using Graph Pad Prism5. 
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5. RESULTS 
Phase-5.1: MCAo (Middle cerebral artery occlusion) surgery optimization 
 
Figure.4: Branches of common carotid artery (CCA)
 
Figure .5: Insertion of the monofilament to ICA through ECA 
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PHASE5.2 BEHAVIOURAL STUDIES 
5.2.1.Neurological deficit score: 
The neurological deficit score was evaluated  after 24hrs of IR and on 7th day.  After 24hrs 
and on 7th day there was significant increase in neurological score in MCAo group (p<0.01) 
is comparison to control group. On 7thday, post traumatic treatment of TDZD-8 (1500µm/kg) 
only showed significant ( p<0.05)  decrease in neurological score  in comparison to MCAo 
group. 
5.2.2.ELEVATED PLUS MAZE: 
5.2.2.1.Effect on time spent in central compartment 
Data are expressed in seconds. MCAo group (p<0.001) showed significant decrease in central 
compartment exploration is comparison to control group indicating increase in anxiety in the 
rat.  There was no significant difference between MCAo and treatment groups.In this 
parameter was observed. 
5.2.2.2.Effect on no of entries in closed arm 
The number of entries made in the closed arms was found to be statistical insignificant     
between groups. 
5.2.2.3.Effect on no of entries in open arm 
MCAo group (p<0.05) showed significant decrease in no of entries made in open arm is 
comparison to control group indicating increased  anxiety of the rat.  There was no significant 
difference between MCAo and treatment groups. 
5.2.2.4.Effect on time spent in closed arm  
Data one expressed in seconds. MCAo group showed significant (p<0.001)  increase  in time 
spent in closed arm when comparison to control group indicating increase in anxiety. AR-A 
(30μg/kg), p<0.01 and (60µm/kg),p<0.001 &TDZD-8(1500mg/kg),p<0.001 showed 
significant decrease in time spent in closed arms in comparison to MCAo group indicating 
the  decrease in angiogenic behaviour. 
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 5.2.2.5.Effect on time spent in open arm 
Data are expressed in seconds. MCAo rats exhibited significant (p<0.001) anxiety behaviour 
is an evidently decrease in time spent in open arm is comparison to control rats. AR-A 
(30µm/kg), p<0.01and (60µm/kg) ,p<0.001 &TDZD-8 (1500µm/kg), (p<0.001) treatment  
significant increase in time spent in open arms is comparison to MCAo group indicating  the 
reversed of anxiety with treatment. 
5.2.3.GRIP STRENGTH: 
Data are expressed in force (gms). MCAo rats (p<0.001) showed significant decrease in force 
applied on the grid  when compared with control group indicaties decrease in muscle tone of 
the rat. AR-A(60µm/kg), p<0.05 &TDZD-8 (1500µm/kg) ,p<0.01  showed  increased in 
muscle tone as observed by increased comparison to MCAo group indicates increase in 
muscle strength of rat. 
5.2.4.OPEN FIELD TEST: 
5.2.4.1Effect on central compartment exploration 
The exploratory activity of different treatment group in central compartment of open field 
exploratory time have shown no significance difference. 
5.2.4.2.Effect on ambulations 
MCAo rats (p<0.001) showed significant decrease in number of ambulations when compared 
to control rats indicating reduced locomotor activity. AR-A (60µm/kg) and TDZD-8 
(1500µm/kg) ,(p<0.01) treatment exibited  significant increase in ambulations in comparison 
to MCAo group indicaties improved locomotor activity. 
5.2.4.3.Effect on grooming&rearing 
The rearing &grooming behaviour of IR rats and different treatments showed no significant 
difference in open field tests. 
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5.2.4.5.Effect on licking 
MCAo rats (p<0.05) showed significant decrease in number of licking behaviour is 
comparison to control group  of the rat.  There was no significant difference with the 
treatment groups in comparison to MCAo rats.  
5.2.4.6.Effect on freezing 
MCAo rats (p<0.001) showed significant increase in freezing time is comparison to vehicle 
treated group indicaties depression the rats.  AR-A (60µm/kg) and TDZD-8 (1500µm/kg) , 
(p<0.001) showed significant decrease freezing behaviour in comparison to MCAo rats 
indicates lower anxiety. 
PHASE.5.3. 
5.3.1.Effect on pro-Inflammatory mediator(TNFα) by ELISA 
Data are expressed in pg/mg protein. MCAo rats showed significant (p<0.001)  increase in 
TNF -α levels when compared to vehicle treated rats indicating increased  inflammatory 
activity. AR-A (60µm/kg), (p<0.01) and TDZD-8 (1500µm/kg) ,(p<0.05) treatment resulted 
in significantly decreased in TNF -α levels in comparison to MCAo rats indicating alteration 
of  inflammation response induced with MCAo. 
5.3.2.Effect on pro-inflammatory mediator(IL 1β ) by ELISA 
Data are expressed in pg/mg protein. MCAo inducement in rats showed significant (p<0.01)  
increase in IL- 1β levels is comparison to control rats indicating increase in inflammatory 
activity .AR-A (60µm/kg), (p<0.01) and TDZD-8 (1500µm/kg) , (p<0.01) showed 
significantly reduced in IL- 1β  levels in comparison to MCAo rats indicating decrease in  
inflammation similarly Significant decrease in  caspase enzyme activity. was observed to 
MCAo rats indicating reduced  cell death or apoptosis. 
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5.4.3.Effect of drug treatment on ratio of GSK- 3β & P GSK- 3β level 
Data are expressed in ratio. MCAo rats (p<0.05) showed significant decrease  in GSK- 3β:p 
gsk-3ß level in comparison to control rats. AR-A (30&60µm/kg ) p<0.001 tratment rats 
expressed  significant increase in GSK 3β:p gsk-3ß ratio is  comparison to MCAo rats. 
5.4.4.Effect of drug treatment on ratio of PAKT:AKT by western blot. 
Data are expressed in ratio. MCAo rats exhibited significant (p<0.05)  decrease  in AKT:p 
AKT ratio in comparison to vehicle traeted rats. Treatment of AR-A (30µM/kg) p<0.05, 
(60µM/kg) ,P<0.01 showed significant increase in AKT:pAKT ratio in comparison to MCAo 
rats . 
5.4.5Effect on caspase activity assay 
Data are expressed as specific activity/µg protein. MCAo rats showed significant (p<0.001)  
increase in caspase enzyme activity in comparison to control rats indicating increase in 
apoptosis (cell death). AR-A (60µm/kg), p<0.01 and TDZD-8 (1500µm/kg) ,p<0.05 showed 
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Results 
BEHAVIOURAL STUDIES: 
Figure:6 Neurological deficit score after 24 hrs          
 
Data are expressed as mean ±SD (n=6). **denotes statistical significance of MCAo group 
compared with control group at p<0.01. 
 
 
 Figure.7.  Neurological deficit score  on 7th day 
 
 
Data are expressed as mean ±SD (n=6). **denotes statistical significance of MCAo group 
compared with control group at p<0.01. #denotes statistical significance of TDZD-8 
(1500µM/kg) treated group compared with MCAo group at p<0.05 respectively 
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 ELEVATED PLUS MAZE 
Figure.8.Effect of drug treatment on time spent in central compartment 
 
Data are expressed as mean ±SD (n=6). Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. ***denotes statistical significance 
of MCAo group compared with control group at p<0.001. 
Figure.9.Effect  of drug treatment on no of entries in closed arm 
 
Data are expressed as mean ±SD (n=6). There is no statistical significance between the 
groups.   
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Figure .10.Effect of drug treatment on no of entries in open arm 
 
Data are expressed as mean ±SD (n=6). *denotes statistical significance of MCAo group 
compared with control group at p<0.05. 
 
Figure.11.Effect of drug treatment on time spent in closed arm 
 
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001.###,##,#denotes statistical significance of AR-A 
(30&60µM/kg), TDZD-8 (1500µM/kg) treated groups compared with MCAo group at 
p<0.001,p<0.01,p<0.05 respectively 
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Figure.12.Effect of drug treatment on time spent in open arm 
 
Data are expressed as mean ±SD (n=6).. ***denotes statistical significance of MCAo group 
compared with control group at p<0.001.###,##,#denotes statistical significance of AR-
A(30&60µM/kg),TDZD-8(1500µM/kg) treated groups compared with MCAo group at 
p<0.001,p<0.01,p<0.05 respectively. 
 
Figure.13.Effect of drug treatment on grip strength                                  
 
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001.##,#denotes statistical significance of AR-
A(60µM/kg),TDZD-8(1500µM/kg) treated groups compared with MCAo group at 
p<0.01,p<0.05 respectively. 
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OPEN FIELD TEST 
Figure.14.Effect of drug treatment on time spent in central compartment 
 
Data are expressed as mean ±SD (n=6). There is no statistical significance between the 
groups.   
 
Figure.15.Effect of drug treatment on no of ambulations 
 
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001.##denotes statistical significance of AR-
A(60µM/kg),TDZD-8(1500µM/kg) treated groups compared with MCAo group at p<0.01 
respectively. 
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Figure.16.Effect of drug treatment on grooming 
 
Data are expressed as mean ±SD (n=6). Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. There is no statistical significance 
between the groups.   
Figure.17.Effect of drug treatment on rearing 
 
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. There is no statistical significance 
between the groups.   
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Figure.18.Effect of drug treatment on licking 
 
Data are expressed as mean ±SD (n=6). *denotes statistical significance of MCAo group 
compared with control group at p<0.05. 
Figure.19.Effect of drug treatment on freezing 
 
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001 .###denotes statistical significance of AR-A 
(60µM/kg), TDZD-8 (1500µM/kg) treated groups compared with MCAo group at p<0.001 
respectively. 
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Figure.20.Effect of drug treatment on pro-inflammatory mediator(TNFα) by ELISA 
 
Data are expressed as mean ±SD (n=3). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001.##,#denotes statistical significance of AR-A 
(60µM/kg), TDZD-8 (1500µM/kg) treated groups compared with MCAo group at 
p<0.01,p<0.05 respectively. 
 
Figure.21.Effect of drug treatment on pro-inflammatory mediator(IL 1β ) by ELISA 
 
Data are expressed as mean ±SD (n=3). **denotes statistical significance of MCAo group 
compared with control group at p<0.01 .##denotes statistical significance of AR-A (60µM/kg) 
,TDZD-8 (1500µM/kg) treated groups compared with MCAo group at p<0.01  respectively. 
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Figure.22.Effect of drug treatment on caspase activity assay 
 
Data are expressed as mean ±SD (n=3).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. ***denotes statistical significance 
of MCAo group compared with control group at p<0.001 .##,#denotes statistical significance 
of AR-A (60µM/kg), TDZD-8 (1500µM/kg) treated groups compared with MCAo group at 
p<0.01,p<0.05 respectively. 
Figure.23.Effect of drug treatment on ratio of GSK 3β & P GSK 3β western blot 
                                         
Data are expressed as mean ±SD (n=3).. *denotes statistical significance of MCAo group 
compared with control group at p<0.05 .###denotes statistical significance of AR-A(30 
&60µM/kg) treated groups compared with MCAo group at p<0.001 respectively. 
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Figure.24.Effect of drug treatment on ratio of PAKT:AKT using western blot 
          
Data are expressed as mean ±SD (n=3). *denotes statistical significance of MCAo group 
compared with control group at p<0.05. ##,#denotes statistical significance of AR-A 
(30&60µM/kg) treated groups compared with MCAo group at p<0.01,P<0.05 respectively. 
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FIGURE.25.  Effect of drug AR-A014418(30&60µm/kg) on ratio of GSK-3β & pGSK-3 
β 
GSK-3β 
 
Control   MCAo  AR-A (30µm/kg) AR-A(60µm/kg) 
 
pGSK-3β 
 
Control   MCAo  AR-A(30µm/kg)  AR-A(60µm/kg) 
  FIGURE.27.  Effect of drug AR-A014418(30&60µm/kg) on  ratio of AKT and pAKT 
AKT 
 
Control   MCAo AR-A(30µm/kg) AR-A(60µm/kg) 
 
pAKT 
 
Control   MCAo         AR-A(30µm/kg) AR-A(60µm/kg) 
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6.DISCUSSION 
The objective of present study is to evaluate the neuroprotective role of GSK-3β inhibitor 
through supressing neuroinflammation in middle cerebral artery occlusion induced transient 
focal cerebral ischemic rat model. Cerebral ischemia is a neurodegenerative disorder where 
insufficient blood flow to brain leads to cell death/excitotoxicity due to oxidative stress,Free 
radical production , inflammation. Ischemic condition led to alteration of multiple of targets 
and pathways including PI3K/AKT1, AKT1/GSK-3β/β-catenin, ERK1/2, apoptotic 
pathways, mTOR pathway  (Schölzke  et al., 2007). Amongst multiple targets, GSK-3β is 
one, which was found prominently active in ischemia. Up-regulation of GSK-3β, post 
translational phosphorylation, and down-stream signaling proteins were involved in 
propagating neuro degeneration during ischemia (Bhat et al., 2012). 
Currently, clinical and pre-clinical studies  of GSK-3 β inhibitors are in progress. Clinical 
trial (Phase-II) on lithium carbonate as a GSK-3 inhibitor is studied by Sao Paulo University 
and The National Institute of Neurological Disorder and Stroke for Alzheimer’s disease 
(AD). A clinical trial for AD including GSK-3β inhibitors, NP12 and NP103, was filed by 
Noscira. A clinical trial on NP-12 (NP031112, tideglusib) has been completed for AD 
whereas; preclinical studies on GSK inhibitors CG-301338 as well as NP-103 are  currently 
in progress ( Serenó et al., 2009). In our study GSK3β competetive inhibitor AR-A 014418 
was treated with two different doses 30µM/kg and 60µM/kg after 24hrs MCAo surgery. 
Further, In this study GSK3β non competetive inhibitor TDZD-8 was  also used at a  dose of 
1500µM/kg. After occlusion of MCA following reperfusion injury MCAo group have 
exhibited increase in neurological deficit score (NDS) when compared to sham operated rats. 
The MCAo group have shown decreased locomtor activity in open field test, decreased 
exploratory, rearing , grooming, no of ambulations indicates that cerebral ischemia have good 
impact on locomotor activity and anxiogenic behaviour. Treatment with GSK3β  inhibitor 
AR-A 014418 and TDZD-8 increased the locomotor activity. 
In the  elevated plus maze test  evaluation of anxiety, MCAO animals showed reduced time 
spent and reduced number of entries in the open arms of maze in comparison to control rats. 
This increase in time and number of entries made in open arm has been correlated with anti-
anxiety-like behaviour, reflecting a conflict between the rodent’s preference for protected 
areas (closed arms of the maze) and their innate motivation to explore novel environments 
(open arms of the maze) (Walf and Frye 2007). In the present study, a positive correlation 
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between GSK3β inhibition and time spent in the open arm of the elevated plus maze explains 
reversal of the ischemia reperfusion injury-induced cognitive deficits and anxiety-like 
behaviour in the MCAO rats. 
A study relating multiple pathways like calcium signaling (S100B – S100 calcium binding 
protein B) kinase pathway (MAPK/JNK-1, -2/p38), inflammatory pathway (NF-κβ, TNF-α, 
COX-2, iNOS and ICAM-1), and typical mitochondrial apoptosis pathway (SOD, 
cytochrome c caspase-9 and Bcl-2) were shown to have direct relation with GSK-3β in 
cerebral ischemia. Inhibition of GSK-3β showed neuroprotection through down-regulation of 
these multiple pathways (Collino et al., 2008). Recent studies have shown that GSK3 has role 
in inflammation by reducing translocation of CREB into the nucleus that leads to increases in 
the expression of pro-inflammatory cytokines such as In IL-1β and TNF-α (Dylan et 
al.,2013). In our study, treatment with GSK3β  inhibitor AR-A 014418 and TDZD-8  
downregulated Interleukin-1-Beta (IL-1β) and Tumor Necrosis Factor -1 alpha (TNF-α) level 
in brain suggest that the GSK3β inhibiton  is beneficial in controling neuro inflammation in 
cerebral ischemic condition.  
GSK-3β inhibition reduces infarct size in adult stroke models and further interacted with pro-
apoptotic transcription factors, such as p53, which upregulates cytochrome C release and Bax 
levels providing more evidence of GSK-3β's pro-apoptotic role following brain injury (Chiu 
and Chuang, 2010). In this study, both competitive and non competitive inhibitors of GSK-3β 
reduced the pro apoptotic caspase 3 activity which is concordance with our previous study, 
GSK-3β inhibition inhibits caspase activity (Darshi et al 2016). GSK-3β activity is 
negatively regulated by several signal transduction cascades that protect neurons against 
apoptosis, including the phosphatidylinositol-3 kinase (PI-3 kinase) pathway. This suggests 
the interesting possibility that activation of GSK3β may contribute to neuronal apoptosis 
(Friedrichs et al.,2011). We found prominent down-regulation of AKT1/GSK-3 β pathway, 
where post-translational phosphorylation was reduced and made AKT1 inactive and GSK-3β 
(increased Ser 9 PGSK 3β levels)in active state. Being these molecules were GSK-3β 
inhibitor, it could not have effect on up-stream regulator AKT1. In contrast, both inhibitors 
showed post-translational phosphorylation in AKT1 and made in active state. These 
observations signified the regulatory loop between GSK-3β and AKT1 which played a role in 
activating AKT1 upon inhibition of GSK-3β. Activation of GSK-3β stabilizes β-arrestin 2, 
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PP2A complex, which is responsible for inactivation of AKT1 and vice versa (O'Brien et 
al.,2011). 
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7. SUMMARY & CONCLUSION 
 Neuroprotective activity of GSK-3ß inhibitors  was evaluated   in cerebral ischemia condition 
by exploring inflammatory and apoptotic pathways 
 MCAo in rats was induced by occluding middle cerebral artery under anesthetic conditions 
and the behavioural parameters were studied at 24hrs and on 7th day 
 GSK- 3ß inhibitors of AR-A014418 (30 & 60 µm/kg) and TDZD-8 (1500 µm/kg) has been 
used as drug to test the neuroprotective action. 
 The behavioural parameters include measurement of neurological deficit through grip 
strength measurement, anxiety behaviour in elevated plus maze and open field exploratory 
test. 
 To support the neuroprotective mechanism of AR-A and TDZD-8 inflammatory markers IL-
1ß, TNF-α were measured through ELISA and  caspase activity assay, protein expression of 
GSK, PGSK, AKT, PAKT was done by Western blot method. 
 Inducement of MCAo in rats have shown decreased locomotor activity, exploratory, rearing, 
grooming behaviour, indicates cerebral ischemia inducement in rats resulted in anxiogenic 
behaviour. 
 The MCAo rats  in elevated plus maze have shown  increase in time spent in closed arm and 
decrease in time spent in open and centre area indicates increased anxiety. 
 Post ischemic administration of AR-A significantly attenuated the behaviour characterised by 
increased locomotor activity, grip strength, grooming, rearing, no of entries and time spent in 
open arm suggesting the AR-A and TDZD-8 protects the brain damage induced by cerebral 
ischemia. 
 Post ischemic administration of AR-A014418 (30&60µm/kg) and TDZD-8 (1500µm/kg) 
significantly reduced the IL-ß and TNF-alpha level. and significantly reduce the caspase-3 
activity  
 Post ischemic administration of AR-A014418(30&60µm/kg) increased the PAKT and PGSK 
levels 
 Treatment with standard GSK-3β inhibitor AR-A014418 stabilizes AKT1/GSK-3β pathway, 
maintains GSK-3β in inactive state, prevents dephosphorylation thus prevents conversion of 
active caspase-3 or inhibits its activity. 
 There is no difference between competitive, non-competitive inhibitors in the GSK-3 β  
mediated activity was observed.  
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